The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...

Gilead Sciences, the maker of a twice-a-year anti-HIV injection, has approached South Africa’s medicine regulator to discuss ...

Explore HIV prevention options for women, including dapivirine rings and dual prevention pills, aiming to reduce infections ...

Cisgender gay and bisexual men, transgender women, and transgender men remain at higher risk for HIV acquisition.

This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...

Imagine a world where an HIV prevention method lasts for six months, offering protection without the daily hassle of taking a ...

This year has seen a double dose of optimism in the field of HIV prevention. First, on 20 June 2024, came the results of the Purpose-1 trial in South Africa and Uganda.1 This randomised controlled ...

Failure to ensure that everyone has access to prevention options to protect oneself from HIV acquisition, has resulted in at ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Given recent approvals and a promising pipeline, new biomedical HIV prevention tools for women have the potential to ...

The Centers for Disease Control and Prevention provides funding for HIV prevention for the populations at the highest risk of ...

In June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. A ...